Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities: A longitudinal multicenter study of a patient cohort

for the Italian Pediatric Allergy Network (I-PAN)

Research output: Contribution to journalArticle

Abstract

Background: Pollen-related seasonal allergic rhinoconjunctivitis (SAR) is a very frequent pediatric disease in Westernized countries. Risk factors and disease phenotypes have been thoroughly examined in several cross-sectional studies. By contrast, only a few studies have examined disease evolution in patient cohorts. We investigated predictive biomarkers of disease evolution in a large cohort of children with SAR. Methods: During 2015-2017 (follow-up), we re-examined 401 patients from those enrolled in 2009-2011 (baseline) by the “Panallergens in Pediatrics” study, a large multicenter survey of Italian children with SAR. Information on clinical history (standard questionnaire, AllergyCARD®; TPS, Italy) and skin prick tests for inhalant and foods extracts (ALK-Abelló, Hørsholm, Denmark) was acquired as at baseline visit. Evolution in clinical and sensitization data of patients was analyzed over time, as well as their association with the main baseline characteristics and atopy risk factors. Results: The average age of participants was 10.4 ± 3.4 years at baseline and 16.2 ± 3.6 years at follow-up. SAR persisted in 93.3% of patients at follow-up and became more frequently associated with asthma (from 36.7% at baseline to 48.6% at follow-up) and oral allergy syndrome (OAS, from 23.4% to 37.7%). Compared to baseline, the prevalence of skin sensitization to some pollens (Phleum pratense, Corylus avellana, Platanus acerifolia, Artemisia vulgaris) and vegetables (hazelnut, wheat, and apple) significantly decreased at follow-up. Earlier onset of SAR and polysensitization at baseline were associated with incident asthma at follow-up. The presence at baseline of serum IgE to the following allergen molecules was identified as biomarkers of clinical evolution: (a) Phl p 1, for persistence of SAR; (b) Phl p 5, for persistence of both rhinitis and asthma; (c) Pru p 3, for new onset of asthma; (d) Bet v 1, for persistence of OAS. Conclusions: Seasonal allergic rhinoconjunctivitis is clinically heterogeneous in its evolution from childhood to adolescence. The detection of serum IgE to specific molecules (Phl p 1, Phl p 5, Bet v 1, Pru p 3) may be useful as biomarkers to predict SAR persistence and future onset of comorbidities, such as asthma and/or OAS.

Original languageEnglish
Pages (from-to)325-334
JournalPediatric Allergy and Immunology
Volume30
Issue number3
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Multicenter Studies
Longitudinal Studies
Comorbidity
Asthma
Biomarkers
Corylus
Pollen
Immunoglobulin E
Phleum
Pediatrics
Artemisia
Malus
Denmark
Rhinitis
Skin Tests
Serum
Vegetables
Allergens
Italy
Triticum

Keywords

  • allergic rhinitis
  • asthma
  • Bet v 1
  • biomarkers
  • children
  • comorbidities
  • IgE
  • longitudinal study
  • Phl p 1
  • Phl p 5
  • pollen
  • prediction
  • Pru p 3

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Immunology

Cite this

Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities : A longitudinal multicenter study of a patient cohort. / for the Italian Pediatric Allergy Network (I-PAN).

In: Pediatric Allergy and Immunology, Vol. 30, No. 3, 01.01.2019, p. 325-334.

Research output: Contribution to journalArticle

@article{7742cd46b09146fdb228624b72c88dd2,
title = "Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities: A longitudinal multicenter study of a patient cohort",
abstract = "Background: Pollen-related seasonal allergic rhinoconjunctivitis (SAR) is a very frequent pediatric disease in Westernized countries. Risk factors and disease phenotypes have been thoroughly examined in several cross-sectional studies. By contrast, only a few studies have examined disease evolution in patient cohorts. We investigated predictive biomarkers of disease evolution in a large cohort of children with SAR. Methods: During 2015-2017 (follow-up), we re-examined 401 patients from those enrolled in 2009-2011 (baseline) by the “Panallergens in Pediatrics” study, a large multicenter survey of Italian children with SAR. Information on clinical history (standard questionnaire, AllergyCARD{\circledR}; TPS, Italy) and skin prick tests for inhalant and foods extracts (ALK-Abell{\'o}, H{\o}rsholm, Denmark) was acquired as at baseline visit. Evolution in clinical and sensitization data of patients was analyzed over time, as well as their association with the main baseline characteristics and atopy risk factors. Results: The average age of participants was 10.4 ± 3.4 years at baseline and 16.2 ± 3.6 years at follow-up. SAR persisted in 93.3{\%} of patients at follow-up and became more frequently associated with asthma (from 36.7{\%} at baseline to 48.6{\%} at follow-up) and oral allergy syndrome (OAS, from 23.4{\%} to 37.7{\%}). Compared to baseline, the prevalence of skin sensitization to some pollens (Phleum pratense, Corylus avellana, Platanus acerifolia, Artemisia vulgaris) and vegetables (hazelnut, wheat, and apple) significantly decreased at follow-up. Earlier onset of SAR and polysensitization at baseline were associated with incident asthma at follow-up. The presence at baseline of serum IgE to the following allergen molecules was identified as biomarkers of clinical evolution: (a) Phl p 1, for persistence of SAR; (b) Phl p 5, for persistence of both rhinitis and asthma; (c) Pru p 3, for new onset of asthma; (d) Bet v 1, for persistence of OAS. Conclusions: Seasonal allergic rhinoconjunctivitis is clinically heterogeneous in its evolution from childhood to adolescence. The detection of serum IgE to specific molecules (Phl p 1, Phl p 5, Bet v 1, Pru p 3) may be useful as biomarkers to predict SAR persistence and future onset of comorbidities, such as asthma and/or OAS.",
keywords = "allergic rhinitis, asthma, Bet v 1, biomarkers, children, comorbidities, IgE, longitudinal study, Phl p 1, Phl p 5, pollen, prediction, Pru p 3",
author = "{for the Italian Pediatric Allergy Network (I-PAN)} and Francesca Cipriani and Salvatore Tripodi and Valentina Panetta and Serena Perna and Ekaterina Potapova and Arianna Dondi and Roberto Bernardini and Carlo Caffarelli and Antonella Casani and Rosa Cervone and Loredana Chini and Pasquale Comberiati and {De Castro}, Giovanna and {Miraglia Del Giudice}, Michele and {Dello Iacono}, Iride and {Di Rienzo Businco}, Andrea and Marcella Gallucci and Arianna Giannetti and Carla Mastrorilli and Viviana Moschese and Simone Pelosi and Ifigenia Sfika and Elena Varin and Valeria Villella and Zicari, {Anna Maria} and Giulia Brindisi and Giampaolo Ricci and Matricardi, {Paolo Maria}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/pai.13036",
language = "English",
volume = "30",
pages = "325--334",
journal = "Pediatric Allergy and Immunology",
issn = "0905-6157",
publisher = "Blackwell Munksgaard",
number = "3",

}

TY - JOUR

T1 - Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities

T2 - A longitudinal multicenter study of a patient cohort

AU - for the Italian Pediatric Allergy Network (I-PAN)

AU - Cipriani, Francesca

AU - Tripodi, Salvatore

AU - Panetta, Valentina

AU - Perna, Serena

AU - Potapova, Ekaterina

AU - Dondi, Arianna

AU - Bernardini, Roberto

AU - Caffarelli, Carlo

AU - Casani, Antonella

AU - Cervone, Rosa

AU - Chini, Loredana

AU - Comberiati, Pasquale

AU - De Castro, Giovanna

AU - Miraglia Del Giudice, Michele

AU - Dello Iacono, Iride

AU - Di Rienzo Businco, Andrea

AU - Gallucci, Marcella

AU - Giannetti, Arianna

AU - Mastrorilli, Carla

AU - Moschese, Viviana

AU - Pelosi, Simone

AU - Sfika, Ifigenia

AU - Varin, Elena

AU - Villella, Valeria

AU - Zicari, Anna Maria

AU - Brindisi, Giulia

AU - Ricci, Giampaolo

AU - Matricardi, Paolo Maria

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Pollen-related seasonal allergic rhinoconjunctivitis (SAR) is a very frequent pediatric disease in Westernized countries. Risk factors and disease phenotypes have been thoroughly examined in several cross-sectional studies. By contrast, only a few studies have examined disease evolution in patient cohorts. We investigated predictive biomarkers of disease evolution in a large cohort of children with SAR. Methods: During 2015-2017 (follow-up), we re-examined 401 patients from those enrolled in 2009-2011 (baseline) by the “Panallergens in Pediatrics” study, a large multicenter survey of Italian children with SAR. Information on clinical history (standard questionnaire, AllergyCARD®; TPS, Italy) and skin prick tests for inhalant and foods extracts (ALK-Abelló, Hørsholm, Denmark) was acquired as at baseline visit. Evolution in clinical and sensitization data of patients was analyzed over time, as well as their association with the main baseline characteristics and atopy risk factors. Results: The average age of participants was 10.4 ± 3.4 years at baseline and 16.2 ± 3.6 years at follow-up. SAR persisted in 93.3% of patients at follow-up and became more frequently associated with asthma (from 36.7% at baseline to 48.6% at follow-up) and oral allergy syndrome (OAS, from 23.4% to 37.7%). Compared to baseline, the prevalence of skin sensitization to some pollens (Phleum pratense, Corylus avellana, Platanus acerifolia, Artemisia vulgaris) and vegetables (hazelnut, wheat, and apple) significantly decreased at follow-up. Earlier onset of SAR and polysensitization at baseline were associated with incident asthma at follow-up. The presence at baseline of serum IgE to the following allergen molecules was identified as biomarkers of clinical evolution: (a) Phl p 1, for persistence of SAR; (b) Phl p 5, for persistence of both rhinitis and asthma; (c) Pru p 3, for new onset of asthma; (d) Bet v 1, for persistence of OAS. Conclusions: Seasonal allergic rhinoconjunctivitis is clinically heterogeneous in its evolution from childhood to adolescence. The detection of serum IgE to specific molecules (Phl p 1, Phl p 5, Bet v 1, Pru p 3) may be useful as biomarkers to predict SAR persistence and future onset of comorbidities, such as asthma and/or OAS.

AB - Background: Pollen-related seasonal allergic rhinoconjunctivitis (SAR) is a very frequent pediatric disease in Westernized countries. Risk factors and disease phenotypes have been thoroughly examined in several cross-sectional studies. By contrast, only a few studies have examined disease evolution in patient cohorts. We investigated predictive biomarkers of disease evolution in a large cohort of children with SAR. Methods: During 2015-2017 (follow-up), we re-examined 401 patients from those enrolled in 2009-2011 (baseline) by the “Panallergens in Pediatrics” study, a large multicenter survey of Italian children with SAR. Information on clinical history (standard questionnaire, AllergyCARD®; TPS, Italy) and skin prick tests for inhalant and foods extracts (ALK-Abelló, Hørsholm, Denmark) was acquired as at baseline visit. Evolution in clinical and sensitization data of patients was analyzed over time, as well as their association with the main baseline characteristics and atopy risk factors. Results: The average age of participants was 10.4 ± 3.4 years at baseline and 16.2 ± 3.6 years at follow-up. SAR persisted in 93.3% of patients at follow-up and became more frequently associated with asthma (from 36.7% at baseline to 48.6% at follow-up) and oral allergy syndrome (OAS, from 23.4% to 37.7%). Compared to baseline, the prevalence of skin sensitization to some pollens (Phleum pratense, Corylus avellana, Platanus acerifolia, Artemisia vulgaris) and vegetables (hazelnut, wheat, and apple) significantly decreased at follow-up. Earlier onset of SAR and polysensitization at baseline were associated with incident asthma at follow-up. The presence at baseline of serum IgE to the following allergen molecules was identified as biomarkers of clinical evolution: (a) Phl p 1, for persistence of SAR; (b) Phl p 5, for persistence of both rhinitis and asthma; (c) Pru p 3, for new onset of asthma; (d) Bet v 1, for persistence of OAS. Conclusions: Seasonal allergic rhinoconjunctivitis is clinically heterogeneous in its evolution from childhood to adolescence. The detection of serum IgE to specific molecules (Phl p 1, Phl p 5, Bet v 1, Pru p 3) may be useful as biomarkers to predict SAR persistence and future onset of comorbidities, such as asthma and/or OAS.

KW - allergic rhinitis

KW - asthma

KW - Bet v 1

KW - biomarkers

KW - children

KW - comorbidities

KW - IgE

KW - longitudinal study

KW - Phl p 1

KW - Phl p 5

KW - pollen

KW - prediction

KW - Pru p 3

UR - http://www.scopus.com/inward/record.url?scp=85063909558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063909558&partnerID=8YFLogxK

U2 - 10.1111/pai.13036

DO - 10.1111/pai.13036

M3 - Article

AN - SCOPUS:85063909558

VL - 30

SP - 325

EP - 334

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

SN - 0905-6157

IS - 3

ER -